3 Dividend Stocks to Hold for the Next 10 Years

The article highlights dividend-paying pharma stocks as long-term buys amid upcoming patent cliffs, led by Bristol Myers Squibb with a forward dividend yield of 3.8% vs the S&P 500’s 1.1%. It argues BMY can offset Eliquis/Opdivo exclusivity losses via new approvals (e.g., Opdivo Qvantig and investigational Milvexian) and expects dividend support. It similarly cites Pfizer’s 6.1% dividend yield as likely sustainable on a large late-stage pipeline (oncology and differentiated weight-loss candidates) and Gilead’s 2.2% forward yield supported by strong HIV franchise momentum and positive phase 3 progress toward an oral once-weekly regimen.

Analysis

The key market mechanism here is not “pharma is cheap,” but a dispersion trade between cash-flow durability and paid-up-for-pipeline optionality. BMY and PFE can look optically attractive on yield, yet that yield is only supportive if replacement revenues arrive before the patent overhang meaningfully compresses the multiple; otherwise the market eventually prices them like ex-growth industrials with a biotech overlay. GILD screens better because the core franchise is more self-funding and less dependent on a single binary launch cycle, which matters when rates stay elevated and investors keep paying up for certainty.

Competitive dynamics are more nuanced than the article implies. In obesity, PFE is effectively entering after the channel, payer, and prescribing habits have already started to ossify around incumbents, so the hurdle is not just efficacy but formulary economics and tolerability differentiation; without that, it risks spending heavily for low-margin relevance. BMY’s life-cycle management can soften the patent cliff, but it mostly defends share rather than expands the addressable market; the real upside is if new formulations reduce friction enough to slow erosion, not if they create a fresh growth leg. For GILD, the larger second-order effect is that any successful longer-acting HIV regimen could force competitors to match convenience rather than price, which favors the company with the broadest installed base and the best transition path.

Contrarian view: the consensus may be overestimating how quickly pipeline narratives become P&L and underestimating how much of these names are still valued on capital-return support. Over the next 1-3 months, the stock reaction will likely be driven by clinical updates and earnings commentary, not headline dividend yields; over 6-18 months, the real test is whether each company can convert pipeline assets into durable free cash flow before the market re-rates them as yield traps. The thesis is falsified by negative late-stage readouts, weaker-than-expected dividend coverage, or any guidance that suggests patent erosion is outpacing new-product adoption.

Key Decisions for Investors

• Prefer long GILD vs. short PFE on a 6-12 month relative basis: GILD has the cleaner cash-flow profile and less binary pipeline dependence; PFE needs multiple positive readouts just to defend current sentiment. Falsify with a strong obesity/oncology data sequence from PFE or unexpected HIV share loss at GILD.
• Use BMY only as a hold/defensive income name, not a re-rating story. If entering, wait for post-earnings weakness and size for yield, with a stop if management commentary implies the franchise-defense curve is slipping faster than expected.
• For event-driven exposure, watch PFE pipeline catalysts rather than buy the stock ahead of them; the risk/reward is asymmetric only if the market is underpricing a genuinely differentiated obesity asset. Otherwise the stock is likely to trade like a value trap until proof of commercial fit emerges.
• Avoid paying up for optionality in the basket here; if you want healthcare beta, own GILD over BMY/PFE on a 6-18 month horizon because the downside from execution misses is lower and the path to sustained FCF is clearer.